Concomitant protein pathogenesis in Parkinson’s disease and perspective mechanisms

Frontiers in Aging Neuroscience

Aging Neuroscience

Yuliang Han¹  Zhuohao He² 

[1] Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China;University of the Chinese Academy of Sciences, Beijing, China;Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China;University of the Chinese Academy of Sciences, Beijing, China;Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China;

关键词: comorbidity;    pathogenesis;    Parkinson’s disease;    mechanism;    synucleinopathies;   

DOI  :  10.3389/fnagi.2023.1189809

 received in 2023-03-20, accepted in 2023-04-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

Comorbidity is a common phenotype in Parkinson’s disease (PD). Patients with PD not only have motor deficit symptoms, but also have heterogeneous non-motor symptoms, including cognitive impairment and emotional changes, which are the featured symptoms observed in patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD) and cerebrovascular disease. Moreover, autopsy studies have also confirmed the concomitant protein pathogenesis, such as the co-existences of α-synuclein, amyloid-β and tau pathologies in PD and AD patients’ brains. Here, we briefly summarize the recent reports regarding the comorbidity issues in PD from both clinical observations and neuropathological evidences. Furthermore, we provide some discussion about the perspective potential mechanisms underlying such comorbidity phenomenon, with a focus on PD and related neurodegenerative diseases.

【 授权许可】

Unknown   
Copyright © 2023 Han and He.